ADC Therapeutics is advancing what’s possible in cancer therapy

adctherapeutics.com
ADC Therapeutics

Confronting cancer with the full potential of our science.

ADC Therapeutics is a commercial-stage biotechnology company dedicated to delivering next-generation ADCs for those affected by cancer. We are pioneers in ADC technology and have a deep understanding of the oncology treatment landscape, and we intend to address significant unmet medical needs and improve outcomes for those with difficult-to-treat cancers.

Our team at ADCT is purpose-driven. We are committed to making a positive impact on patients’ lives with our innovative ADC products. We have over a decade of experience in the field of ADCs and we are expanding our technology toolbox to ensure we harness the full potential of ADCs to address the unmet medical needs of patients with cancer.

Ameet Mallik
Chief Executive Officer, ADC Therapeutics

We are confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families.

We strive to be a leading antibody drug conjugate company that transforms the lives of those impacted by cancer.

ADC Therapeutics founded as a spinoff from Spirogen Ltd, an early innovator in PBD-based ADC research

Our History

- MAY 2020 - ADC Therapeutics joins the NYSE as ticker ADCT
- OCT 2019 - 1st patient enrolled in Phase 2 clinical trial of CD-25 targeted investigational compound in relapsed or refractory Hodgkin lymphoma
- DEC 2020 - ADC Therapeutics and Overland Pharmaceuticals form Overland ADCT BioPharma to develop and commercialize ADC products, including loncastuximab tesirine-lpyl, in greater China and Singapore
- JUN 2011 - ADC Therapeutics founded as a spinoff from Spirogen Ltd, an early innovator in PBD-based ADC research
- MAY 2020 - ADC Therapeutics joins the NYSE as ticker ADCT
- OCT 2019 - 1st patient enrolled in Phase 2 clinical trial of CD-25 targeted investigational compound in relapsed or refractory Hodgkin lymphoma
- MAR 2016 - 1st patient enrolled in Phase 1 clinical trial of lead investigational compound targeting CD-19 (loncastuximab tesirine-lpyl) in positive B-Cell non-Hodgkin lymphoma
- AUG 2018 - 1st patient enrolled in pivotal Phase 2 trial with loncastuximab tesirine-lpyl
- JUN 2011 - ADC Therapeutics founded as a spinoff from Spirogen Ltd, an early innovator in PBD-based ADC research

antibody drug conjugate (ADC)
biosimilars
license application (BLA)
pyrrolobenzodiazepine (PBD)
One of the ways we are delivering on the promise of science – 
advancing next-generation PBD-based ADCs.

Our proprietary PBD-based ADCs are expected to provide a novel way to treat hematological cancers and solid tumors, address significant unmet medical needs, and improve the lives of patients with cancer.

The antibody drug conjugate (ADC) binds to a specific tumor cell surface antigen and is internalized. The potent pyrrolobenzodiazepine (PBD) dimer toxin is released inside the cell, where it then creates a covalent cross-link between the strands of the DNA double helix. Because these cross-links do not distort the DNA structure, it is hypothesized that they remain invisible to repair mechanisms and can covertly persist to interrupt cell division and cause tumor cell death.

References
Scan the QR code to view the ADC Therapeutics pipeline or visit adctherapeutics.com

For general inquiries, please contact info@adctherapeutics.com

For more information about our clinical trials and research, please contact medicalinformation@ADCTherapeutics.com, or call 1.855.690.0340